Fight CRC Clinical Trial Finder
| NCT ID | Title | Phase | Date Added | Location | Prior IO Allowed | CRC-directed | Status | Drugs | Tags |
|---|---|---|---|---|---|---|---|---|---|
| NCT ID NCT05019534 |
TitleTolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | Phase
Phase 1
|
Date Added 2021-08-25 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Camrelizumab, Cetuximab Injection [Erbitux], Vemurafenib Oral Tablet [Zelboraf] |
Tags
MSS/ MMRp
|
| NCT ID NCT04591431 |
TitleThe Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy | Phase
Phase 2
|
Date Added 2020-10-19 |
Location
Italy
|
Prior IO Allowed No |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Alectinib, Atezolizumab, Brigatinib, Cobimetinib, Entrectinib, Erlotinib, everolimus, Ipatasertib, Ipilimumab, Itacitinib, Lapatinib, Nivolumab, Oncology Drugs, palbociclib, Pemigatinib, Pertuzumab, Ponatinib, Trastuzumab, Trastuzumab emtansine, Vemurafenib, Vismogedib |
Tags
MSS/ MMRp
|
| NCT ID NCT03985891 |
TitleThe Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer | Phase
Phase 1/Phase 2
|
Date Added 2019-06-14 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Anti-PD-1 Monoclonal Antibody JS001, Chemotherapy |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04984369 |
TitleThe Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment | Phase
Phase 2
|
Date Added 2021-07-30 |
Location
China
|
Prior IO Allowed Yes |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Cetuximab Injection [Erbitux], HLX208 |
Tags
MSS/ MMRp
|
| NCT ID NCT02925234 |
TitleThe Drug Rediscovery Protocol (DRUP Trial) | Phase
Phase 2
|
Date Added 2016-10-05 |
Location
Netherlands
|
Prior IO Allowed Yes |
CRC-directed No |
Status
Recruiting
|
Drugs
Abemaciclib, afatinib, Alectinib, Alpelisib, Atezolizumab and Bevacizumab, Axitinib, Cabozantinib, Crizotinib, Dabrafenib, Dabrafenib and trametinib, Dacomitinib, durvalumab, Entrectinib, Erdafitinib, Erlotinib, Ipilimumab and nivolumab, Lenvatinib, lorlatinib, Nilotinib, Nivolumab, Olaparib, palbociclib, panitumumab, Pembrolizumab, Regorafenib, ribociclib, Rucaparib, Sunitinib, Talazoparib, Trametinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT04535024 |
TitleThe Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in MSS Oligometastatic Colorectal Cancer | Phase
Phase 2
|
Date Added 2020-09-01 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Sintilimab |
Tags
MSS/ MMRp
|
| NCT ID NCT04948034 |
TitleThe Combination of Fruquintinib, Tislelizumab and Stereotactic Ablative Radiotherapy in Metastatic Colorectal Cancer(RIFLE) | Phase
Phase 2
|
Date Added 2021-07-01 |
Location
China
|
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Fruquintinib, Tislelizumab |
Tags
MSI-H/ MMRd, MSS/ MMRp
|
| NCT ID NCT02298959 |
TitleTesting the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | Phase
Phase 1
|
Date Added 2014-11-24 |
Location
Florida, United States
Maryland, United States Massachusetts, United States Canada |
Prior IO Allowed No |
CRC-directed Yes |
Status
Active, not recruiting
|
Drugs
Pembrolizumab, Ziv-Aflibercept, Keytruda, Zaltrap |
Tags
MSS/ MMRp
|
| NCT ID NCT03502733 |
TitleTesting the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma | Phase
Phase 1
|
Date Added 2018-04-19 |
Location
Maryland, United States
Texas, United States |
Prior IO Allowed Yes |
CRC-directed No |
Status
Active, not recruiting
|
Drugs
Copanlisib, Ipilimumab, Nivolumab, Aliqopa, Opdivo |
Tags
MSS/ MMRp
|
| NCT ID NCT05673148 |
TitleTesting the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study | Phase
Phase 3
|
Date Added 2023-01-06 |
Location
Arizona, United States
California, United States Delaware, United States District of Columbia, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Iowa, United States Kentucky, United States Maryland, United States Michigan, United States Minnesota, United States Mississippi, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States North Dakota, United States Ohio, United States Oklahoma, United States Pennsylvania, United States South Dakota, United States Tennessee, United States Texas, United States Utah, United States Washington, United States Wisconsin, United States |
Prior IO Allowed No |
CRC-directed Yes |
Status
Recruiting
|
Drugs
Chemotherapy |
Tags
MSS/ MMRp
|
